Clinical Trial Update: The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bevacizumab, serplulimab, and rmhTNF-NC for malignant ascites; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Bevacizumab (bevacizumab)
• Serplulimab (serplulimab)
• rmhTNF-NC (rmhTNF-NC)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Malignant Ascites | Phase 2 | Status: RECRUITING